Considering ERK1/2 are active in epithelial cancers, including breast cancer, if ERK1/2 requires autocrine activation of EGFR, than the therapeutic blockade of EGFR will block ERK1/2-driven tumorigenic responses. Here, MAPK3 is linked to breast carcinoma.